Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06287463 · ClinicalTrials.gov registry record · Phase 1
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
A Phase 1 study, sponsored by Deciphera Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT06287463 is a Phase 1 study that was terminated before completion, run by Deciphera Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT06287463, a Phase 1 study, was terminated before completion, sponsored by Deciphera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
Interventions
- DRUG DCC-3084
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2024-05-14 |
| Est. Completion | 2026-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06287463
The ClinicalTrials.gov registry entry for NCT06287463 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DCC-3084 is the first listed.
NCT06287463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06287463 about?
NCT06287463 is a clinical study titled "Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway". This is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol...
What is the current status of trial NCT06287463?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2024-05-14. Estimated completion is 2026-02-13.
What interventions are being tested in trial NCT06287463?
The interventions under investigation include: DCC-3084 (DRUG).
Who is sponsoring clinical trial NCT06287463?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.